China Pharma: Candesartan Tablets Passes Generic-drug-consistency-evaluation

August 09, 2023 — 08:39 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - China Pharma Holdings, Inc. (CPHI) said its subsidiary Hainan Helpson Medical & Biotechnology Co. has received the Drug Supplementary Application Approval Notice for its candesartan tablets by National Medical Products Administration of China, or NMPA, indicating that the company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs.

Candesartan is an angiotensin II antagonist, suitable for primary hypertension, and is the smallest dose of sartan drugs. It is used to maintain stable blood pressure control for 24 hours; reduce the risk of morning spikes caused by blood pressure fluctuations; reduce target organ damage caused by blood pressure fluctuations; help to reduce the hospitalization risk and mortality rate of patients with chronic heart failure, and improve symptoms and exercise ability.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

China Pharma: Candesartan Tablets Passes Generic-drug-consistency-evaluation

Tags

Latest Articles